WUXI BIOLOGICS (CAYMAN) INC financial statements, including revenue, expenses, profit, and loss
The total revenue of 2269 for the last semiannual is 9.23 B HKD, and it's 3.91% lower compared to the previous semiannual. The net income of H2 23 is 1.22 B HKD.